Anebulo gets $1.9M cooperative grant award from NIDA for intravenous selonabant

Anebulo Pharmaceuticals has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9M from the National Institute on Drug Abuse NIDA part of the National Institutes of Health NIH to support the development of intravenous selonabant, for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression in children. The grant comes in the form of two tranches with the initial award of $0.9 million and subsequent funding of approximately $1M subject to certain milestones. The grant was awarded under NIH award number 1U01DA059995-01. “We are honored to receive this cooperative grant award from NIDA to support the further development of intravenous selonabant,” commented Ken Cundy, CSO of Anebulo Pharmaceuticals. “We believe this provides additional validation of the significant and growing unmet medical need for an emergency antidote to cannabis. Acute cannabis exposure in children represents a potentially life-threatening condition that can result in CNS depression, respiratory depression, coma, and in rare cases death. Research has shown that children are much more sensitive to the toxic effects of cannabis. Younger children have an underdeveloped endocannabinoid system with significantly more of the primary cannabinoid receptor type 1 receptors present in their brains. As a direct consequence, pediatric cannabis ingestion can result in much more serious outcomes than in adults, and a much greater risk of hospitalization and admission to intensive care.”